Abstract
The epidemiology of benign prostatic hyperplasia (BPH) is complex and not fully understood. The androgenic hormones testosterones and dihydrotestosterone play at least a permissive and important role. Growth factors and other hormones including estrogens may also play a role. BPH is a truely hyperplastic process resulting in growth of glandular-epithelial and stromal/muscle tissue in the prostate, leading to often measurable growth taking on different shapes and configurations which may impact symptoms and secondary outcomes. It is important to recognize that BPH is a histological conditions, which is one but not the only cause of lower urinary tract symptoms, and may or may not be associated with prostate enlargement and bladder outlet obstruction. Recognizing the different entities and determining their presence in individual patients may help with therapeutic decision making.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Roehrborn C, McConnell J . Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh P, Retik A, Vaughan E, Wein A (eds). Campbell's Urology, 8th edn. Saunders: Philadelphia, 2002, pp 1297–1336.
Cunha GR . Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. [Review]. Cancer 1994; 74: 1030–1044.
McConnell JD . Prostatic growth: new insights into hormonal regulation. [Review]. Br J Urol 1995; 76 (Suppl 1): 5–10.
Wilson JD, Roehrborn C . Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts. J Clin Endocrinol Metab 1999; 84: 4324–4331.
Peters CA, Walsh PC . The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia [published erratum appears in N Engl J Med 1988; 318(9): 580]. N Engl J Med 1987; 317: 599–604.
Marberger M, Roehrborn CG, Marks LS, Wilson T, Rittmaster RS . Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91: 1323–1328.
Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004; 172 (4 Pt 1): 1399–1403.
Martikainen P, Kyprianou N, Isaacs JT . Effect of transforming growth factor-beta on proliferation and death of rat prostatic cells. Endocrinology 1990; 127: 2963–2968.
Kyprianou N, Isaacs JT . ‘Thymineless’ death in androgen-independent prostatic cancer cells. Biochem Biophys Res Commun 1989; 165: 73–81.
Barrack ER, Bujnovszky P, Walsh PC . Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues: characterization of nuclear salt-resistant receptors. Cancer Res 1983; 43: 1107–1116.
Rennie PS, Bruchovsky N, Goldenberg SL . Relationship of androgen receptors to the growth and regression of the prostate. Am JClin Oncol 1988; 11 (Suppl 2): S13–S17.
Walsh PC, GM H, LL E . Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supernormal. J Clin Invest 1983; 72: 1772–1777.
Russell DW, Wilson JD . Steroid 5alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994; 63: 25.
Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE . Steroid 5 alpha reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186: 1213.
Carson III C, Rittmaster R . The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003; 61 (4 Suppl 1): 2–7.
Lee KL, Peehl DM . Molecular and cellular pathogenesis of benign prostatic hyperplasia. J urol 2004; 172 (5 Pt 1): 1784–1791.
Griffiths K . Molecular control of prostate growth. In: Kirby R, McConnell J, Fitzpatrick JM, Roehrborn CG, Boyle P (eds). Textbook of Benign Prostatic Hyperplasia. Isis Medical Media: Oxford, 1996, pp 23–56.
Story MT, Livingston B, Baeten L, Swartz SJ, Jacobs SC, Begun FP et al. Cultured human prostate-derived fibroblasts produce a factor that stimulates their growth with properties indistinguishable from basic fibroblast growth factor. Prostate 1989; 15: 355–365.
Lawson RK . Role of growth factors in benign prostatic hyperplasia. Eur Urol 1997; 32 (Suppl 1): 22–27.
McNeal JE . Origin and evolution of benign prostatic enlargement. Invest Urol 1978; 15: 340.
McNeal J . Pathology of Benign Prostatic Hyperplasia. Insight into Etiology. In: Lepor H, Walsh PC (eds). The Urologic Clinics of North America, 17th edn. WB Saunders Company: Philadelphia, 1990, pp 477–486.
Caine MLS . The ‘capsule’ in benign prostatic hypertrophy. US Department of Health and Human Services 1987; No. 87-2881: 221.
Shapiro E, Becich MJ, Hartanto V, Lepor H . The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 1992; 147: 1293–1297.
Shapiro E, Hartanto V, Lepor H . Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis. J Urol 1992; 147: 1167–1170.
Roehrborn CG, Schwinn DA . Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004; 171: 1029–1035.
Lepor H, Tang R, Shapiro E . The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate 1993; 22: 301–307.
Lepor H, Tang R, Meretyk S, Shapiro E . Alpha1 adrenoceptor subtypes in the human prostate. J Urol 1993; 149: 640–642.
Uckert S, Kuthe A, Stief CG, Jonas U . Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J Urol 2001; 19: 14–22.
McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401–1407.
McVary KT . Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005; 47: 838–845.
McVary KT, Razzaq A, Lee C, Venegas MF, Rademaker A, McKenna KE . Growth of the prostate gland is facilitated by the autonomic system. Biol Reprod 1994; 51: 99–107.
Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC . The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol 1979; 121: 640–642.
Azadzoi KM, Radisavljevic ZM, Siroky MB . Effects of ischemia on tachykinin-containing nerves and neurokinin receptors in the rabbit bladder. Urology 2008; 71: 979–983.
Azadzoi KM, Yalla SV, Siroky MB . Oxidative stress and neurodegeneration in the ischemic overactive bladder. J Urol 2007; 178: 710–715.
Oishi K, Boyle P, Barry M, Farah R, Gu F-L, Jacobsen S et al. Epidemiology and natural history of benign prostatic hyperplasia. In: 4th International Consultation on Benign Prostatic Hyperplasia. Plymbridge Distributors Ltd: Plymouth, United Kingdom, 1998, pp 23–59.
Girman CJ . Natural history and epidemiology of benign prostatic hyperplasia: relationship among urologic measures. Urology 1998; 51 (4A Suppl): 8–12.
Girman CJ, Epstein RS, Jacobsen SJ, Guess HA, Panser LA, Oesterling JE et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994; 44: 825–831.
Girman CJ, Jacobsen SJ, Guess HA, Oesterling JE, Chute CG, Panser LA et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 1995; 153: 1510–1515.
Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM . Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999; 35: 277–284.
McConnell J, Committee TMS . The long term effects of medical therapy on the progression of BPH: results from the MTOPS trial. J urol 2002; 167 (4 Suppl): 265A.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Roehrborn, C. Pathology of benign prostatic hyperplasia. Int J Impot Res 20 (Suppl 3), S11–S18 (2008). https://doi.org/10.1038/ijir.2008.55
Published:
Issue Date:
DOI: https://doi.org/10.1038/ijir.2008.55
This article is cited by
-
Association between sleep quality and benign prostate hyperplasia among middle-aged and older men in India
BMC Public Health (2023)
-
Overview of Benchtop Models for Comparison of Surgical Treatments for Benign Prostatic Hyperplasia
Current Urology Reports (2023)
-
A cross-sectional quality assessment of TikTok content on benign prostatic hyperplasia
World Journal of Urology (2023)
-
Machine learning based on radiomics features combing B-mode transrectal ultrasound and contrast-enhanced ultrasound to improve peripheral zone prostate cancer detection
Abdominal Radiology (2023)
-
Genetically elevated bioavailable testosterone level was associated with the occurrence of benign prostatic hyperplasia
Journal of Endocrinological Investigation (2023)